Literature DB >> 8600091

Radiobiological evidence suggesting heterogeneous microdistribution of boron compounds in tumors: its relation to quiescent cell population and tumor cure in neutron capture therapy.

K Ono1, S I Masunaga, Y Kinashi, M Takagaki, M Akaboshi, T Kobayashi, K Akuta.   

Abstract

PURPOSE: The heterogeneous microdistribution of boron compounds in tumors and its significance on tumor cure were examined by a radiobiological procedure. The role of quiescent (Q) cells in tumor was especially investigated. METHODS AND MATERIALS: 10B-enriched paraboronophenylalanine (BPA) and mercaptoundecahydrododecaborate (BSH) were administered to SCCVII tumor bearing C3H/He mice by intragastric and i.v. injections, respectively. The continued effects of these boron compounds with thermal irradiations were studied by using colony formation and tumor control assays. Their effects on Q cells were also analyzed by the combined method of micronucleus frequency assay and an identification of proliferating (P) cells by BUdR and anti-BUdR monoclonal antibody.
RESULTS: 10B-concentration after BPA (1,500 mg/kg) and BSH (75 mg/kg) administration were 11 ppm at 3 h and 10.5 ppm at 30 min, respectively. Cell survival decreased exponentially with an increment of neutron fluence (phi). The exponential parts of the curves were: -InSF = -0.052+ 13.0x10(13)phi, -InSF = -0.032+7.68X10(-13)phi, and -InSF = -0.0005+2.68x10(-13)phi for BPA-BNCT, BSH-BNCT, and NCT alone, respectively. Fifty percent tumor control was obtained at the influence of 10.2 x 10(12) n/cm2 in BPA-BNCT. On the other hand, 11.4 x 10(12) n/cm2 of neutrons had to be delivered in BSH-BNCT. The normal nuclear division fraction defined as the cell fraction that did not express micronuclei at first mitosis after treatment was investigated. The surviving cell fraction and the normal nuclear division fraction were regarded as equal in NCT alone. However, the normal nuclear division factor following BPA-BNCT was greater than the surviving cell fraction, and the difference increased with an increase in neutron fluence. In Q cells, BSH-BNCT yielded higher micronucleus frequency than BPA-BNCT and NCT alone. The frequencies in Q cells following BPA-BNCT and NCT alone were almost same as that in total cell population after NCT alone.
CONCLUSIONS: Our data suggested that BPA distributed in tumors hetergeneously. Q cells especially might not accumulate BPA. To decrease the possible disadvantage of BPA-BNCT, the combination of BPA and BSH or other neutron capture element that emit particles with longer ranges, for example, gadolinium, would have to be investigated.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8600091     DOI: 10.1016/0360-3016(95)02180-9

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  24 in total

1.  Preferential recurrence of a sarcomatous component of a gliosarcoma after boron neutron capture therapy: case report.

Authors:  Shin-Ichi Miyatake; Hiroko Kuwabara; Yoshinaga Kajimoto; Shinji Kawabata; Kunio Yokoyama; Atsushi Doi; Motomu Tsuji; Hiroshi Mori; Koji Ono; Toshihiko Kuroiwa
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

2.  Analysis of boron neutron capture reaction sensitivity using Monte Carlo simulation and proposal of a new dosimetry index in boron neutron capture therapy.

Authors:  Satoshi Takeno; Hiroki Tanaka; Koji Ono; Takashi Mizowaki; Minoru Suzuki
Journal:  J Radiat Res       Date:  2022-09-21       Impact factor: 2.438

3.  The early successful treatment of glioblastoma patients with modified boron neutron capture therapy. Report of two cases.

Authors:  Shinji Kawabata; Shin-Ichi Miyatake; Yoshinaga Kajimoto; Yuzo Kuroda; Toshihiko Kuroiwa; Yoshio Imahori; Mitsunori Kirihata; Yoshinori Sakurai; Tohru Kobayashi; Koji Ono
Journal:  J Neurooncol       Date:  2003-11       Impact factor: 4.130

4.  Boron neutron capture therapy demonstrated in mice bearing EMT6 tumors following selective delivery of boron by rationally designed liposomes.

Authors:  Peter J Kueffer; Charles A Maitz; Aslam A Khan; Seth A Schuster; Natalia I Shlyakhtina; Satish S Jalisatgi; John D Brockman; David W Nigg; M Frederick Hawthorne
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-27       Impact factor: 11.205

5.  DNA damage induced by boron neutron capture therapy is partially repaired by DNA ligase IV.

Authors:  Natsuko Kondo; Yoshinori Sakurai; Yuki Hirota; Hiroki Tanaka; Tsubasa Watanabe; Yosuke Nakagawa; Masaru Narabayashi; Yuko Kinashi; Shin-ichi Miyatake; Masatoshi Hasegawa; Minoru Suzuki; Shin-ichiro Masunaga; Takeo Ohnishi; Koji Ono
Journal:  Radiat Environ Biophys       Date:  2015-11-16       Impact factor: 1.925

6.  Biodistribution of sodium borocaptate (BSH) for boron neutron capture therapy (BNCT) in an oral cancer model.

Authors:  Marcela A Garabalino; Elisa M Heber; Andrea Monti Hughes; Sara J González; Ana J Molinari; Emiliano C C Pozzi; Susana Nievas; Maria E Itoiz; Romina F Aromando; David W Nigg; William Bauer; Verónica A Trivillin; Amanda E Schwint
Journal:  Radiat Environ Biophys       Date:  2013-04-17       Impact factor: 1.925

Review 7.  Boron neutron capture therapy for malignant brain tumors.

Authors:  Shin-Ichi Miyatake; Masahiko Wanibuchi; Naonori Hu; Koji Ono
Journal:  J Neurooncol       Date:  2020-07-16       Impact factor: 4.130

8.  Fluorine-18-labeled boronophenylalanine positron emission tomography for oral cancers: Qualitative and quantitative analyses of malignant tumors and normal structures in oral and maxillofacial regions.

Authors:  Yasunori Ariyoshi; Masashi Shimahara; Yoshihiro Kimura; Yuichi Ito; Takeshi Shimahara; Shin-Ichi Miyatake; Shinji Kawabata
Journal:  Oncol Lett       Date:  2011-03-10       Impact factor: 2.967

9.  Pharmacokinetic study of BSH and BPA in simultaneous use for BNCT.

Authors:  Kunio Yokoyama; Shin-Ichi Miyatake; Yoshinaga Kajimoto; Shinji Kawabata; Atsushi Doi; Toshiko Yoshida; Tomoyuki Asano; Mitsunori Kirihata; Koji Ono; Toshihiko Kuroiwa
Journal:  J Neurooncol       Date:  2006-03-24       Impact factor: 4.130

10.  Sonoporation as an enhancing method for boron neutron capture therapy for squamous cell carcinomas.

Authors:  Naofumi Yamatomo; Takaki Iwagami; Itsuro Kato; Shin-Ichiro Masunaga; Yoshinori Sakurai; Soichi Iwai; Mitsuhiro Nakazawa; Koji Ono; Yoshiaki Yura
Journal:  Radiat Oncol       Date:  2013-12-02       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.